TY - JOUR
T1 - Anti–immunoglobulin E for food allergy
AU - Dantzer, Jennifer A.
AU - Wood, Robert A.
N1 - Funding Information:
Funding: The authors have no funding sources to report.
Publisher Copyright:
© 2023 American College of Allergy, Asthma & Immunology
PY - 2023/7
Y1 - 2023/7
N2 - Objective: To review the safety and efficacy of anti–immunoglobulin E (IgE) monotherapy or as an adjunct to oral immunotherapy (OIT) in the treatment of IgE-mediated food allergy. Data Sources: Literature searches were performed using the Excerpta Medica dataBASE, Medline, Scopus, and PubMed Central to identify articles in English related to food allergy and anti-IgE therapies, including omalizumab and ligelizemab. Study Selections: Original research articles reviewed include interventional studies, retrospective and prospective observational studies, peer-reviewed reviews, and systematic reviews. Data were reviewed and summarized. Results: Here, we discuss the current anti-IgE therapies being studied as a potential treatment option for food allergy. We also review trial design, safety, and efficacy data on the use of anti-IgE therapies as monotherapy or in combination with OIT for food allergies. Finally, we discuss clinical trials in progress using omalizumab and ligelizumab and highlight important clinical considerations. Conclusion: Over the past 20 years, substantial progress has been made in understanding the potential role of anti-IgE therapies for food allergy. Anti-IgE therapies seem to be a promising option that may increase reaction dose thresholds and decrease time to reach OIT maintenance and OIT dosing-related reactions. Two phase 3 trials are currently in progress studying anti-IgE potential monotherapy for the treatment of peanut and multifood allergies. It is important for clinicians to be aware of these emerging treatment options.
AB - Objective: To review the safety and efficacy of anti–immunoglobulin E (IgE) monotherapy or as an adjunct to oral immunotherapy (OIT) in the treatment of IgE-mediated food allergy. Data Sources: Literature searches were performed using the Excerpta Medica dataBASE, Medline, Scopus, and PubMed Central to identify articles in English related to food allergy and anti-IgE therapies, including omalizumab and ligelizemab. Study Selections: Original research articles reviewed include interventional studies, retrospective and prospective observational studies, peer-reviewed reviews, and systematic reviews. Data were reviewed and summarized. Results: Here, we discuss the current anti-IgE therapies being studied as a potential treatment option for food allergy. We also review trial design, safety, and efficacy data on the use of anti-IgE therapies as monotherapy or in combination with OIT for food allergies. Finally, we discuss clinical trials in progress using omalizumab and ligelizumab and highlight important clinical considerations. Conclusion: Over the past 20 years, substantial progress has been made in understanding the potential role of anti-IgE therapies for food allergy. Anti-IgE therapies seem to be a promising option that may increase reaction dose thresholds and decrease time to reach OIT maintenance and OIT dosing-related reactions. Two phase 3 trials are currently in progress studying anti-IgE potential monotherapy for the treatment of peanut and multifood allergies. It is important for clinicians to be aware of these emerging treatment options.
UR - http://www.scopus.com/inward/record.url?scp=85153392339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153392339&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2023.03.030
DO - 10.1016/j.anai.2023.03.030
M3 - Review article
C2 - 37031775
AN - SCOPUS:85153392339
SN - 1081-1206
VL - 131
SP - 11
EP - 22
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 1
ER -